Targeted apoptosis induction in hemato-oncology
Promotie: dhr. B. ten Cate, 16.15 uur, Academiegebouw, Broerstraat 5, Groningen
Proefschrift: Targeted apoptosis induction in hemato-oncology
Promotor(s): prof.dr. L.F.M.H. de Leij
Faculteit: Medische Wetenschappen
Contact: via de persvoorlichters van het UMCG, tel. 050-361 2200, e-mail: voorlichting bvl.umcg.nl
Targeted apoptosis induction in hemato-oncology
Leukemia is characterized by the uncontrolled overproduction of white blood cells. The five years survival rate for some distinct types of leukemia is only 20%. This poor prognosis is due to the lack of effective therapies as well as to therapy-related mortality. Therefore, the aim of this research was to develop novel targeted therapies which effectively eliminate leukemia cells while sparing normal cells. In this respect we have utilized antibodies, since antibodies can selectively bind to and eliminate leukemia cells. Currently, a number of antibodies are already applied in the clinic; however enhancement of their anti-leukemia activity is necessary. Using recombinant DNA technology we have fused antibody fragments with the pro-apoptotic proteins TRAIL and FasL. TRAIL and FasL are immune effector molecules involved in the elimination of cancer cells. The clinical application of TRAIL and FasL for leukemia therapy is hampered due to the wide-spread expression of their cognate receptors. Therefore, we have generated fusion proteins comprising a leukemia-selective antibody fragment genetically linked with either TRAIL or FasL. Due to the leukemia-specific antibody fragment these fusion proteins accrete at the cell surface of leukemia cells and thereby redirect TRAIL and FasL to these leukemia cells. Our studies indicate that these fusion proteins potently eliminate leukemia cells, without apparent toxicity towards normal cells. Furthermore, by applying different antibody fragments in our fusion proteins we were able to target and eliminate cells of several distinct types of leukemia. The ultimate goal is to develop these fusion proteins for clinical applications.
Last modified: | 13 March 2020 01.16 a.m. |
More news
-
06 June 2025
India-Netherlands Hydrogen Valley Fellowship Programme announced
To coincide with World Environment Day, 5 June 2025, the Indian Department of Science and Technology and the University of Groningen yesterday announced a Hydrogen Valley Fellowship Programme Partnership, allowing talented Indian scholars working on...
-
24 March 2025
UG 28th in World's Most International Universities 2025 rankings
The University of Groningen has been ranked 28th in the World's Most International Universities 2025 by Times Higher Education. With this, the UG leaves behind institutions such as MIT and Harvard. The 28th place marks an increase of five places: in...
-
05 March 2025
Women in Science
The UG celebrates International Women’s Day with a special photo series: Women in Science.